PROSTAT SPESİFİK ANTİJEN 2.5-4 NG/ML ARALIĞINDA PSAD VE PROSTAT BİYOPSİ SONUÇLARININ DEĞERLENDİRİLMESİ Evaluation of PSAD and Prostate Biopsy Results in Prostat Specific Antigen Between 2.5-4 ng/mL
Öz
ÖZET
Amaç: Bu çalışmanın amacı; PSA 2.5- 4 ng/ml arasında olan hastaların verilerini ve bu aralıkta
kanser saptama oranını değerlendirmektir.
Gereç ve Yöntemler: Ocak 2011-Aralık 2014 tarihleri arasında hastanemizde Prostat Kanseri
(PCa) şüphesi olan ve total PSA değeri 2.5-4 ng/ml olan 83 hastadan alınan prostat biyopsi
sonuçları retrospektif olarak değerlendirildi. PSA yüksekliği ve/veya anormal rektal muayene
bulgusu ile kliniğimize başvuran her hastaya transrektal ultrason eşliğinde prostat biyopsisi uygulandı.
Hastaların yaşları, total PSA değerleri, PSAD, prostat volümleri, parmakla rektal muayeneleri
ve prostat biyopsisi sonuçları retrospektif olarak değerlendirildi.
Sonuç: Hastaların ortalama yaşı 64.1±8.3 (43-78) idi. 0rtalama PSA degerleri 3.1±0.8 ng/ml
idi. 16 hastada prostat kanseri saptandı. 67 hastada benign patolojiler saptandı. Prostat kanseri
saptanan hastaların yaşları, PSA, PSAD, prostat volümleri sırası ile; 63.1±9.4. 3.34±0.37.
0.06±0.01, 50.1±9.6 idi. Prostat kanseri saptanmayan grupta ise bu değerler; 64.4±8.6,
3.23±0.4, 0.05±0.01, 66.1±17.7 idi. Yalnızca prostat boyutu; prostat kanseri saptanan hastalarda
anlamlı olarak küçük saptandı. 22 hastada anormal rektal muayene bulgusu saptandı.
16 (%19.2) hastada prostat kanseri saptandı. Hastaların ortalama gleason skoru 6.5 (6-8) idi.
Tartışma: PSA 2.5-4 ng/ml aralığında kanser saptama oranımız literatürle uyumlu bulunmuştur.
Bu hastaların klinik olarak tedavi edilmesi gerektiğini düşünmekteyiz. Bu nedenle 2.5 ng/ml
PSA seviyesinde hastalara prostat biyopsisi yapılması gerektiği düşüncesindeyiz.
Anahtar Sözcükler: Prostat spesifik antijen 2.5-4ng/ml; Prostat kanseri; Prostat biyopsisi
ABSTRACT
Objective: The aim of this study; we retrospective analyzed data of the results of prostate
biopsy of patients who had the prostate specific antigen (PSA) levels between 2.5- 4 ng/ml and
we evaluate to the cancer detection rate in this range.
Material and Methods: Between January 2011 and December 2014, prostate biopsy results
from 83 patients with a total PSA level of 2.5-4 ng / mL, which were suspected to be PCA in
our hospital, were evaluated retrospectively.Each patient underwent transrectal ultrasound
guided prostate biopsy. The age, total PSA, prostate volume, digital rectal examination and
pathology result were evaluated for each patient.
Results: The mean age of the patients was 64.1 ± 8.3 (43-78). Mean PSA values were 3.1 ±
0.8 ng/ml. Prostate cancer was detected in 16 patients. Benign pathologies were detected
in 67 patients. Patients with prostate cancer is detected; Ages, PSA, PSAD, prostate volumes;
63.1 ± 9.4, 3.34 ± 0.37, 0.06 ± 0.01, 50.1 ± 9.6, respectively. In the group without prostate
cancer, these values were; 64.4 ± 8.6, 3.23 ± 0.4, 0.05 ± 0.01, 66.1 ± 17.7, respectively. Only
small prostate size was found significant in prostate cancer patients.Abnormal digital rectal
examination was found in 22(%26) patients .Prostate cancer was detected in 16 (19.2%)
patients. Gleason score of Prostate cancer patients were 6.5 (6-8).
Conclusion: Our cancer detection rate in PSA range 2.5-4 ng / ml was found to be consistent
with the literature. We think that these cancers should also be treated clinically. For this reason
we suggest to do prostate biopsy for patients who have PSA level over 2.5 ng / ml.
Keywords: Prostate-specific antigen 2.5-4ng/ml; Prostate cancer; Prostate biopsy
Kaynakça
- Printz C. Many unknowns in low-risk prostate cancer treatment. Ongoing studies and biomarker research may shed light on best approach. Cancer. 2009;115:4645-6. 2. Wang MC, Valenzuala LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol. 1979;17: 159. 3. Lilja II: A kallikrein like serin protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin İnvest. 1985;76: 1899. 4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng J Med. 1987;317: 909. 5. Brawer MK: Laboratory studies for the detection of carcinoma of prostate. Urol Clin North Am. 1990;17: 759-67. 6. Stamey TA: PSA in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr Urol. 1989;10: 49-50. 7. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int. 2005;95:545-8. 8. National Collaborating Centre for Cancer. Prostate cancer
Öz
Kaynakça
- Printz C. Many unknowns in low-risk prostate cancer treatment. Ongoing studies and biomarker research may shed light on best approach. Cancer. 2009;115:4645-6. 2. Wang MC, Valenzuala LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol. 1979;17: 159. 3. Lilja II: A kallikrein like serin protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin İnvest. 1985;76: 1899. 4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng J Med. 1987;317: 909. 5. Brawer MK: Laboratory studies for the detection of carcinoma of prostate. Urol Clin North Am. 1990;17: 759-67. 6. Stamey TA: PSA in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr Urol. 1989;10: 49-50. 7. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int. 2005;95:545-8. 8. National Collaborating Centre for Cancer. Prostate cancer
Ayrıntılar
| Bölüm | Orjinal Çalışma |
|---|---|
| Yazarlar | |
| Yayımlanma Tarihi | 10 Eylül 2017 |
| Yayımlandığı Sayı | Yıl 2017 Cilt: 7 Sayı: 3 |